by Delthia Ricks , Medical Xpress Credit: Science Immunology (2024). DOI: 10.1126/sciimmunol.adp3720 An investigational therapy is demonstrating preclinical promise against non-Hodgkin lymphoma by boosting natural killer cells and efficiently annihilating the malignancy without toxicity to the patient, a team of cancer biologists in France has found. The emerging therapy is for B cell non-Hodgkin lymphoma, the most common form...
Tag: <span>Hodgkin’s lymphoma</span>
Post
ASH: A+AVD beats ABVD for advanced Hodgkin’s lymphoma
(HealthDay)—For patients with advanced-stage Hodgkin’s lymphoma, brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (A+AVD) have superior efficacy to doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD), according to a study published online Dec. 10 in the New England Journal of Medicine to coincide with the annual meeting of the American Society of Hematology, held from Dec. 9 to 12 in...